Wave Life Sciences Ltd. (WVE)
| Market Cap | 1.39B +38.0% |
| Revenue (ttm) | 71.80M -31.6% |
| Net Income | -183.59M |
| EPS | -1.03 |
| Shares Out | 192.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,541,270 |
| Open | 7.35 |
| Previous Close | 7.29 |
| Day's Range | 7.09 - 7.42 |
| 52-Week Range | 5.02 - 21.73 |
| Beta | -1.32 |
| Analysts | Strong Buy |
| Price Target | 28.88 (+300.0%) |
| Earnings Date | Apr 28, 2026 |
About WVE
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc... [Read more]
Financial Performance
In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $28.88, which is an increase of 300.00% from the latest price.
News
Wave Life Sciences price target lowered to $24 from $30 at Citi
Citi analyst Samantha Semenkow lowered the firm’s price target on Wave Life Sciences (WVE) to $24 from $30 and keeps a Buy rating on the shares. Published first on TheFly
Wave Life Sciences price target lowered to $43 from $52 at Canaccord
Canaccord lowered the firm’s price target on Wave Life Sciences (WVE) to $43 from $52 and keeps a Buy rating on the shares. The firm said headed into the next
Wave Life Sciences price target lowered to $19 from $21 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Wave Life Sciences (WVE) to $19 from $21 and keeps a Buy rating on the shares. Following the Q1 report,
Wave Life Sciences assumed with a Buy at Truist
Truist assumed coverage of Wave Life Sciences (WVE) with a Buy rating and price target of $15, down from $50. The firm says the reduced price target reflects higher risk
Wave Life Sciences price target lowered to $36 from $39 at Clear Street
Clear Street lowered the firm’s price target on Wave Life Sciences (WVE) to $36 from $39 and keeps a Buy rating on the shares following the Q1 report. The firm
Wave Life Sciences Earnings Call Transcript: Q1 2026
Lead programs for obesity, AATD, and liver disease advanced with strong clinical data and regulatory progress. Revenue surged 315% year-over-year, net loss narrowed, and cash runway extends into Q3 2028. Multiple pivotal trials and data readouts are planned for 2026.
Wave Life Sciences reports Q1 EPS (13c), consensus (31c)
Reports Q1 revenue $38.25M, consensus $7.92M. “We’re accelerating WVE-007 to the next stages of development following the improvements in body composition already observed in the Phase 1 portion of ou...
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the tri...
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences announces hearing on proposed redomicilation
As previously announced, Wave Life Sciences (WVE) is seeking shareholders’ and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of ...
Wave Life Sciences Announces Proposed Redomiciliation to the United States
CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences price target lowered to $18 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Wave Life Sciences (WVE) to $18 from $30 and keeps a Buy rating on the shares. The firm believes
Wave Life Sciences price target lowered to $15 from $27 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on Wave Life Sciences (WVE) to $15 from $27 and keeps an Outperform rating on the shares as part of
Wave Life Sciences removed from Best Ideas List at Wedbush
Wedbush removed Wave Life Sciences (WVE) from its Best List Ideas due to the firm’s investment price discipline. Wedbush has an Outperform rating on the shares. Published first on TheFly
Wave Life Sciences price target lowered to $21 from $38 at BofA
BofA lowered the firm’s price target on Wave Life Sciences (WVE) to $21 from $38 and keeps a Buy rating on the shares after the company announced updated data for
Wave Life Sciences price target lowered to $13 from $27 at Wells Fargo
Wells Fargo lowered the firm’s price target on Wave Life Sciences (WVE) to $13 from $27 and keeps an Overweight rating on the shares. The firm has less conviction that
Wave Life Sciences price target lowered to $39 from $50 at Clear Street
Clear Street lowered the firm’s price target on Wave Life Sciences (WVE) to $39 from $50 but keeps a Buy rating on the shares. The stock is down after reporting
Wave Life Sciences price target lowered to $25 from $35 at Leerink
Leerink analyst Joseph Schwartz lowered the firm’s price target on Wave Life Sciences (WVE) to $25 from $35 and keeps an Outperform rating on the shares. The firm still likes
Wave Life Sciences stock crash: why analyst sees a buying opportunity
Wave Life Sciences (NASDAQ: WVE) shares have been cut in half on Thursday, even though the biotechnology company reported Phase 1 data for an obesity drug that management dubbed “positive”. The sudden...
Wave Life Sciences price target lowered to $18 from $28 at Jefferies
Jefferies lowered the firm’s price target on Wave Life Sciences (WVE) to $18 from $28 and keeps a Buy rating on the shares. The negative stock reaction following the company’s
Wave Life Sciences falls -54.6%
Wave Life Sciences (WVE) is down -54.6%, or -$6.71 to $5.58. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
Leerink analyst Mani Foroohar notes that Wave Life Sciences’ (WVE) updated Phase 1 WVE-007 data showed placebo-adjusted visceral fat loss at the 240mg dose, but total fat mass and lean
WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave ...
Wave Life Sciences falls -57.6%
Wave Life Sciences (WVE) is down -57.6%, or -$7.09 to $5.21. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing